Intratumoral gene transfer of immunomodulatory antibody combinations: a preclinical proof-of-concept study KU Leuven
Immune checkpoint inhibitors have emerged as a new promising treatment modality for cancer, as these monoclonal antibodies (mAbs) have been shown to enable durable responses in patients with various advanced and metastatic tumors. Still, a large proportion of cancer patients are refractory to this type of immunotherapy, which has led to a surging interest in combination treatments to improve response rates. These combination treatments, ...